A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices
ID Number 08-1093-00003Principal Investigator(s)
Alan J. Moskowitz
Department(s) or Division(s)
Health Evidence and Policy
The purpose of this study is to evaluate the administration of TTP889 in patients following LVAD (Left Ventricular Assist Device) implantation by examining its effects on thrombin generation markers. This Phase II trial should support a Phase III trial in evaluating the efficacy and safety of this agent to address some of the most serious adverse events related to coagulation with current LVAD therapy.
Recruiting Patients: No